Dermata Therapeutics (DRMA) Competitors $5.19 +0.54 (+11.61%) Closing price 03:59 PM EasternExtended Trading$5.28 +0.09 (+1.64%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRMA vs. BFRG, FLGC, BIVI, COCP, CMMB, TRAW, GELS, IMNN, NBY, and PHIOShould you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Bullfrog AI (BFRG), Flora Growth (FLGC), BioVie (BIVI), Cocrystal Pharma (COCP), Chemomab Therapeutics (CMMB), Traws Pharma (TRAW), Gelteq (GELS), Imunon (IMNN), NovaBay Pharmaceuticals (NBY), and Phio Pharmaceuticals (PHIO). These companies are all part of the "pharmaceutical products" industry. Dermata Therapeutics vs. Its Competitors Bullfrog AI Flora Growth BioVie Cocrystal Pharma Chemomab Therapeutics Traws Pharma Gelteq Imunon NovaBay Pharmaceuticals Phio Pharmaceuticals Dermata Therapeutics (NASDAQ:DRMA) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability. Which has better earnings & valuation, DRMA or BFRG? Bullfrog AI has higher revenue and earnings than Dermata Therapeutics. Bullfrog AI is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDermata TherapeuticsN/AN/A-$12.29M-$16.41-0.32Bullfrog AI$60K241.73-$6.99M-$0.76-1.86 Do insiders & institutionals believe in DRMA or BFRG? 8.7% of Dermata Therapeutics shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 18.5% of Dermata Therapeutics shares are held by insiders. Comparatively, 24.7% of Bullfrog AI shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts prefer DRMA or BFRG? Dermata Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 92.68%. Given Dermata Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dermata Therapeutics is more favorable than Bullfrog AI.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dermata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Bullfrog AI 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is DRMA or BFRG more profitable? Bullfrog AI's return on equity of -195.35% beat Dermata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dermata TherapeuticsN/A -214.98% -153.76% Bullfrog AI N/A -195.35%-162.37% Does the media favor DRMA or BFRG? In the previous week, Bullfrog AI had 3 more articles in the media than Dermata Therapeutics. MarketBeat recorded 4 mentions for Bullfrog AI and 1 mentions for Dermata Therapeutics. Dermata Therapeutics' average media sentiment score of 1.91 beat Bullfrog AI's score of 0.48 indicating that Dermata Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Dermata Therapeutics Very Positive Bullfrog AI Neutral Which has more volatility & risk, DRMA or BFRG? Dermata Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. SummaryDermata Therapeutics beats Bullfrog AI on 8 of the 14 factors compared between the two stocks. Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRMA vs. The Competition Export to ExcelMetricDermata TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.17M$3.08B$5.64B$10.33BDividend YieldN/A2.44%5.79%4.65%P/E Ratio-0.3221.1975.7526.14Price / SalesN/A457.15557.16132.69Price / CashN/A44.6837.1160.83Price / Book0.849.7412.416.36Net Income-$12.29M-$52.93M$3.29B$270.97M7 Day Performance-4.42%3.87%1.26%0.36%1 Month Performance-5.64%7.65%3.84%6.37%1 Year Performance-66.52%20.14%61.01%28.46% Dermata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRMADermata Therapeutics2.7613 of 5 stars$5.19+11.6%$10.00+92.7%-70.0%$3.17MN/A-0.328Positive NewsHigh Trading VolumeBFRGBullfrog AI1.0677 of 5 stars$1.37-7.4%N/A-50.9%$14.04M$60K-1.804News CoverageGap UpFLGCFlora Growth3.1555 of 5 stars$24.04-28.3%$93.00+286.9%-57.8%$13.92M$52.37M-0.70280Gap DownHigh Trading VolumeBIVIBioVie0.4301 of 5 stars$1.84-2.6%N/A-85.0%$13.86MN/A-0.0210News CoverageUpcoming EarningsCOCPCocrystal Pharma2.169 of 5 stars$1.31+0.8%$6.00+358.0%-26.5%$13.45MN/A-1.0610CMMBChemomab Therapeutics3.3063 of 5 stars$2.60-1.1%$26.50+919.2%-58.9%$13.45MN/A-1.1020TRAWTraws Pharma1.2153 of 5 stars$1.88-1.6%N/A-73.3%$13.27M$230K0.0217News CoverageGELSGelteqN/A$1.38+0.7%N/AN/A$13.03M$100K0.00N/APositive NewsGap UpIMNNImunon2.1873 of 5 stars$5.11-0.8%$232.50+4,449.9%-65.7%$12.47M$500K-0.3930NBYNovaBay Pharmaceuticals0.8546 of 5 stars$2.14+1.4%$0.85-60.3%+210.1%$12.46M$9.78M-0.0430News CoverageDividend AnnouncementPHIOPhio Pharmaceuticals2.7543 of 5 stars$2.17-3.1%$14.00+545.2%-34.3%$12.43MN/A-0.6710 Related Companies and Tools Related Companies BFRG Competitors FLGC Competitors BIVI Competitors COCP Competitors CMMB Competitors TRAW Competitors GELS Competitors IMNN Competitors NBY Competitors PHIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRMA) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRMA Stock Alerts